Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 61 Equity-to-Asset is 0.83 as of Mar. 2026, which is 1% above its 10-year median of 0.82. GuruFocus rates KKPCF with a GF Score™ of 61/100 and a GF Value™ of $26.63. The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks better than 84.72% on this metric.
Kaken Pharmaceutical Co (OTCPK:KKPCF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kaken Pharmaceutical Co Equity-to-Asset Related Terms
Kaken Pharmaceutical Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's Equity-to-Asset falls into.
Kaken Pharmaceutical Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kaken Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (KKPCF) has a Equity-to-Asset of 0.83 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kaken Pharmaceutical Co and its competitors. This is near median its historical median of 0.82. Over the past decade, Kaken Pharmaceutical Co's Equity-to-Asset has ranged from 0.75 to 0.84. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #154 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Kaken Pharmaceutical Co's Equity-to-Asset too high?
Kaken Pharmaceutical Co's current Equity-to-Asset of 0.83 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 0.84. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Kaken Pharmaceutical Co's value of 0.83 is 38.3% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #154 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #154 out of 1008 companies for Equity-to-Asset. This places Kaken Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Kaken Pharmaceutical Co's value of 0.83 is 38.3% above this benchmark. Historically, Kaken Pharmaceutical Co's own Equity-to-Asset has ranged from 0.75 to 0.84 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.60, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current Equity-to-Asset of 0.83 is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current Equity-to-Asset is 0.83, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current Equity-to-Asset of 0.83. The stock's GF Value™ is $26.63, compared to a current price of $26.00 — trading 2.4% below its estimated fair value. The current Equity-to-Asset is 0.83, which is near median its 10-year median of 0.82 and 38.3% above the Drug Manufacturers industry median of 0.60. Kaken Pharmaceutical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current Equity-to-Asset is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be undervalued.
The current stock price of $26.00 is trading 2.4% below its estimated GF Value™ of $26.63.
Key valuation signals for KKPCF:
Equity-to-Asset: 0.83 (near median its 10-year median of 0.82)
GF Value™: $26.63 vs. price of $26.00 (2.4% below fair value)
Industry Position: 38.3% above the Drug Manufacturers median (#154 of 1008)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
61GF Score
Get the complete analysis for KKPCF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
